These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 354732)

  • 1. Serum calcium and magnesium in schizophrenia: relationship to clinical phenomena and neuroleptic treatment.
    Alexander PE; Van Kammen DP; Bunney WE
    Br J Psychiatry; 1978 Aug; 133():143-9. PubMed ID: 354732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum calcium and magnesium levels in chronic schizophrenics.
    Athanassenas G; Papadopoulos E; Kourkoubas A; Tsitourides S; Gabriel J; Hoïdas S; Frangos E
    J Clin Psychopharmacol; 1983 Aug; 3(4):212-6. PubMed ID: 6886033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms.
    Alexander PE; van Kammen DP; Bunney WE
    Arch Gen Psychiatry; 1979 Nov; 36(12):1372-7. PubMed ID: 496555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of hypermagnesaemia to activity and neuroleptic drug therapy in schizophrenic states.
    Brackenridge CJ; Jones IH
    J Neurol Neurosurg Psychiatry; 1971 Apr; 34(2):195-9. PubMed ID: 5571604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and cerebrospinal levels of calcium and magnesium in acute versus remitted schizophrenic patients.
    Levine J; Rapoport A; Mashiah M; Dolev E
    Neuropsychobiology; 1996; 33(4):169-72. PubMed ID: 8840338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy.
    Baastrup PC; Christiansen C; Transbøl I
    Neuropsychobiology; 1980; 6(1):56-9. PubMed ID: 6102745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of neuroleptic drug treatment on plasma fibrinogen concentrations in schizophrenic states.
    Brackenridge CJ; Jones IH
    J Neurol Neurosurg Psychiatry; 1968 Aug; 31(4):326-9. PubMed ID: 5684392
    [No Abstract]   [Full Text] [Related]  

  • 9. Pimozide in the treatment of chronic schizophrenic patients.
    Chouinard G; Lehmann HE; Ban TA
    Curr Ther Res Clin Exp; 1970 Sep; 12(9):598-603. PubMed ID: 4989691
    [No Abstract]   [Full Text] [Related]  

  • 10. [Report on the clinical testing of the delayed-action form of the neuroleptic agent moperone hydrochloride in 20 chronic psychotic patients].
    Lydecken K
    Schweiz Arch Neurol Neurochir Psychiatr; 1977; 120(1):75-82. PubMed ID: 323966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.
    Morris PA; MacKenzie DH; Masheter HC
    Br J Psychiatry; 1970 Dec; 117(541):683-4. PubMed ID: 4923721
    [No Abstract]   [Full Text] [Related]  

  • 12. Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment.
    Lichtshtein D; Dobkin J; Ebstein RP; Biederman J; Rimon R; Belmaker RH
    Br J Psychiatry; 1978 Feb; 132():145-8. PubMed ID: 623945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
    Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of the long-acting injectable neuroleptic, fluspirilene, in the treatment of schizophrenic and mentally retarded patients.
    Zwanikken GJ; Remans B; Dewulf P; Amery W
    Acta Psychiatr Scand; 1971; 47(3):334-48. PubMed ID: 4946910
    [No Abstract]   [Full Text] [Related]  

  • 15. [Time relationship between the appearance of persisting extrapyramidal hyperkineses and psychotic recurrences following sudden interruption of prolonged neuroleptic therapy of chronic schizophrenic patients].
    Degkwitz R; Bauer MP; Gruber M; Hampel G; Luxenburger O; Richartz M; Wenzel W
    Arzneimittelforschung; 1970 Jul; 20(7):890-3. PubMed ID: 4918918
    [No Abstract]   [Full Text] [Related]  

  • 16. Penfluridol (R 16341). A long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients. A placebo-controlled double-blind trial.
    Zwanikken GJ
    Psychiatr Neurol Neurochir; 1973; 76(2):83-92. PubMed ID: 4573494
    [No Abstract]   [Full Text] [Related]  

  • 17. Pimozide compared with fluphenazine in schizophrenia.
    Kenway AK; Masheter HC
    Br J Clin Pract; 1971 Feb; 25(2):69-72. PubMed ID: 4927983
    [No Abstract]   [Full Text] [Related]  

  • 18. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Open and double-blind study of a new neuroleptic with prolonged action: pimozide (R 6238)].
    Goldwurm G; Cocchi A; Perosino N; Rossella E; Terranova R
    Clin Ter; 1971 Jun; 57(5):431-9. PubMed ID: 5113574
    [No Abstract]   [Full Text] [Related]  

  • 20. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.